Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levodropropizine controlled release - Hyundai Pharmaceutical

Drug Profile

Levodropropizine controlled release - Hyundai Pharmaceutical

Alternative Names: HOB-048; Levotuss CR

Latest Information Update: 14 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hyundai Pharmaceutical
  • Class Antitussives; Small molecules
  • Mechanism of Action Neuropeptide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cough

Most Recent Events

  • 14 Oct 2021 Discontinued - Phase-III for Cough in South Korea (PO) (Hyundai Pharmaceuticals pipeline, October 2021)
  • 01 Oct 2018 Hyundai Pharm completes a phase III trial in Cough in South Korea (PO, Tablet, Syrup) (NCT03489837)
  • 23 Jan 2018 Levodropropizine controlled release is still in phase III trials for Cough in South Korea (Hyundai Pharmaceuticals pipeline, January 2018)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top